
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular is a financially sound company with a strong Q1 performance and potential for external growth in the cardiac market. Their expanding gross margin and international sales strategy, accompanied by investments in R&D and potential acquisitions, showcase their commitment to continued growth and success in the future. However, potential challenges in complying with international regulations and obtaining necessary certifications must be closely monitored.
Bears say
LeMaitre Vascular is experiencing lackluster distribution sales in 2026 due to the discontinuation of Aziyo distribution, which has led to lower-than-average sales and unit pressure. Additionally, while the company has posted record sales in all product categories, they have only seen organical growth of less 12.8% due to lower distribution sales. Lastly, the company has filed for early cannulation labeling with the FDA, but their future financial performance may be impacted by investment in Artegraft and other operational and sales initiatives.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares